BioPlus Specialty Pharmacy

Overview

BioPlus Specialty Pharmacy is the specialty-pharmacy arm of CarelonRx inside Elevance Health, operating after the 2023 acquisition; CarelonRx has centralized its specialty-pharmacy story under the BioPlus brand, so buyers searching for CarelonRx Specialty Pharmacy or Kroger Specialty Pharmacy should evaluate BioPlus as the active brand. BioPlus traces back to a 1989 Florida specialty and infusion business, became part of CarePathRx in 2020, and moved to Elevance in 2023.

BioPlus is not an independent launch-specialist specialty pharmacy and not a PBM-neutral channel. The buyer value is pairing limited-distribution access with payer-owned channel position inside the Elevance / CarelonRx ecosystem; the trade-off is that channel-steering, data governance, and hub coordination need explicit RFP guardrails for any manufacturer that also runs PBM-owned competitors in the network.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, BioPlus Specialty Pharmacy is evaluated as specialty-pharmacy arm of CarelonRx inside Elevance Health, operating after the 2023 acquisition; CarelonRx has centralized its specialty-pharmacy story under the BioPlus brand, so buyers searching for CarelonRx Specialty Pharmacy or Kroger Specialty Pharmacy should evaluate BioPlus as the active brand.

Capability	Buyer should compare	BioPlus Specialty Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Core fulfillment handoff. National specialty-pharmacy footprint with more than 100 limited-distribution medication relationships cited in public acquisition materials.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Core coverage workflow. Two-hour patient acceptance positioning for referral intake, PA support, and triage; specify therapy-specific BI / PA and abandonment SLAs in the RFP.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Engagement model. Therapy management, refill outreach, adherence support, and disease-state coverage across oncology, rare disease, autoimmune, neurology, hepatitis C, HIV, transplant, and infusion-adjacent categories.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Documented for biologics and infusion-adjacent. REMS-relevant workflows, cold-chain and complex medication management, and coordination with infusion-adjacent CarelonRx assets; validate CGT scope per product.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Confirm reporting layer in the RFP. Specify dispense files, abandonment reporting, adherence metrics, cadence, and how payer-owned routing affects reporting boundaries inside CarelonRx.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent. 340B program support for covered entities is a documented offering; confirm infusion and provider-office coordination scope within the CarelonRx network.

Buyer Fit

• Best buying context: A manufacturer that wants specialty pharmacy access inside Elevance / CarelonRx covered lives and is comfortable with a payer-owned channel alongside independent and wholesaler-owned SPs.
• Best-fit buyers: Mid- and large-cap pharma access teams running multi-product specialty portfolios where payer adjacency, 340B covered-entity workflows, and referral speed are material decision factors.
• Less ideal fit: Launch teams that need a PBM-neutral specialty pharmacy with no payer-ownership questions; BioPlus may still belong in the network, but it is not the right primary partner for that posture.
• Commercial fit: Pricing is undisclosed; assume an RFP-led scope with SLAs, channel-steering guardrails, data governance, and hub coordination terms defined at contract.
• Profile signal: Specialty-pharmacy footprint expanded with Kroger Specialty Pharmacy integration; Indianapolis facility expansion under an $11.9M investment with 230 planned jobs; ranked among Drug Channels’ top 15 U.S. pharmacies of 2025.
• Pre-award diligence: Confirm payer-plan routing, channel-steering guardrails, data firewalling with CarelonRx, hub handoffs, 340B reporting separation, and the remediation posture following the prior BioPlus data incident.

Differentiators

• CarelonRx / Elevance ownership: Specialty-pharmacy path inside one of the largest U.S. payer / PBM ecosystems rather than an independent channel.
• 100+ limited-distribution medication relationships: Public acquisition materials cite an LDD network broader than the standalone brand visibility implies.
• Two-hour patient acceptance positioning: A concrete service-level claim buyers can test during contracting and implementation rather than a generic speed-to-therapy claim.
• 340B program support for covered entities: Specialty-pharmacy workflow, reporting, and compliance offering that extends reach into health-system and FQHC use cases.
• Kroger Specialty Pharmacy footprint integration: Elevance’s Kroger Specialty Pharmacy transaction enlarged the BioPlus-centered specialty platform with additional licensed dispensing capacity.

RFP Questions

• Which products and therapeutic areas are currently in BioPlus’s limited-distribution network?
• Which payer lives can BioPlus access through CarelonRx, and where does anti-steering or network design constrain routing?
• What is the expected referral-to-acceptance, PA, dispense, and first-fill timeline by therapy type?
• Which patient-status, abandonment, refill, adherence, and adverse-event data fields will be returned to the manufacturer, and at what cadence?
• How are 340B prescriptions, health-system referrals, and payer-owned routes separated in reporting?
• How will BioPlus coordinate with the manufacturer’s hub or competing specialty pharmacies, and what channel-steering guardrails are contractually enforceable?
• What security and privacy remediation has followed the previously reported BioPlus data incident, and what is the current attestation posture?

Recent Activity

• 2026 - Mark Montgomery, who led BioPlus through the Elevance integration, joined Elevate Health Technologies’ board.
• 2025 - BioPlus appeared among finalists for MMIT’s Specialty Pharmacy Patient Choice Awards in the retail specialty pharmacy category and ranked among Drug Channels’ top 15 U.S. pharmacies of 2025.
• 2024-2025 - CarelonRx continued integrating specialty assets, including the Kroger Specialty Pharmacy footprint, into the BioPlus-centered specialty platform.
• 2024 - Elevance announced an $11.9 million Indianapolis investment tied to BioPlus expansion and 230 planned jobs by the end of 2025.
• 2023 - Elevance Health completed the acquisition of BioPlus from CarePathRx and folded it into CarelonRx.